Panion & BF Biotech Inc (1760) — Cash Flow Quality Index
Panion & BF Biotech Inc (1760) has a Cash Flow Quality Index of 0.70x as of September 2025. Operating cash flow of NT$73.31 Million is below net income of NT$104.58 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Panion & BF Biotech Inc (1760) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Panion & BF Biotech Inc Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Panion & BF Biotech Inc across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Panion & BF Biotech Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Panion & BF Biotech Inc (2009–2024)
Year-by-year earnings quality comparison for Panion & BF Biotech Inc. For live market cap and the full company financial profile, see 1760 market cap overview.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.62x | NT$351.19 Million | NT$217.44 Million | ▼ -29.7% |
| 2023 | 2.30x | NT$177.42 Million | NT$77.22 Million | ▼ -14.5% |
| 2022 | 2.69x | NT$489.87 Million | NT$182.34 Million | ▲ +22.3% |
| 2021 | 2.20x | NT$401.23 Million | NT$182.65 Million | ▲ +1449.3% |
| 2020 | -0.16x | NT$-14.55 Million | NT$89.41 Million | ▼ -140.5% |
| 2019 | 0.40x | NT$90.98 Million | NT$226.29 Million | ▲ +25.0% |
| 2018 | 0.32x | NT$78.58 Million | NT$244.38 Million | ▼ -59.6% |
| 2017 | 0.80x | NT$113.97 Million | NT$143.14 Million | ▼ -41.8% |
| 2016 | 1.37x | NT$177.22 Million | NT$129.42 Million | ▲ +172.9% |
| 2015 | 0.50x | NT$58.30 Million | NT$116.19 Million | ▼ -50.8% |
| 2014 | 1.02x | NT$76.11 Million | NT$74.57 Million | ▼ -72.5% |
| 2013 | 3.72x | NT$86.22 Million | NT$23.20 Million | ▼ -94.0% |
| 2009 | 62.08x | NT$76.98 Million | NT$1.24 Million | — |